GENE ONLINE|News &
Opinion
Blog

2021-03-31| Asia-Pacific

Korea Made Humira Biosimilar Begins Sales in Australia, Marks its Presence in Third Overseas Market

by Tyler Chen
Share To

After launching in Canada in February, Korea’s Samsung Bioepis began selling HUMIRA’s biosimilar HADLIMA (adalimumab) in Australia in partnership with MSD Australia (Merck & Co. in the U.S. and Canada).

 

What is Adalimumab?

Adalimumab is an anti-TNF biosimilar of AbbVie’s hot-selling drug Humira that is approved for numerous indications. They include rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and plaque psoriasis.

Adalimumab is Samsung Bioepis’s third anti-TNF biosimilar approved in the US, following BRENZYS (etanercept) and RENFLEXIS (infliximab) in 2016 and 2017 respectively. Meanwhile, adalimumab is also Samsung Bioepis’s fourth biosimilar overall to be approved in the US after RENFLEXIS, ONTRUZANT (trastuzumab-dttb), and ETICOVO (etanercept-ykro).

 

Collaboration with Biogen and Merck & Co.

Before entering the market in Australia, adalimumab was firstly sold under the name of IMRALDI in Europe in 2018 in partnership with Biogen.

It was then launched in Canada working with Merck Canada in February 2021. This came after Samsung Bioepis’ agreement with Merck & Co. in 2013 where Samsung Bioepis will be in charge of clinical trials, manufacturing, and regulatory registration of the drug, and Merck & Co. will handle the commercialization and approval in partnered countries.

 

Clinical Trial Data Leading to FDA Approval

Adalimumab is currently approved in 6 countries: Australia, Canada, Europe, Switzerland, the US, and Korea. The FDA approval is a result of positive data from a Phase 3 clinical trial conducted in 544 patients with moderate to severe rheumatoid arthritis despite methotrexate (MTX) therapy.

After randomly receiving adalimumab or the reference product in Week 24, the drug arm expressed a similar response rate with the reference group (72.4% vs. 72.2%). The efficacy, safety, and immunogenicity profiles of the drug were comparable to that of the reference.

Related Article: Lilly Partners with Samsung Biologics to Boost Delivery of COVID-19 Antibody Treatments

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Convergence, Communication and Commercialization, The Cornerstones In Emerging Regulatory Trends
2022-05-24
FDA Rejects Emergency Use Authorization for Common and Inexpensive Antidepressant COVID-19 Treatment
2022-05-20
FDA Allows Resumption of Gilead’s Lenacapavir AIDS Trials
2022-05-19
LATEST
Flagship-Backed ProFound Launches With $75 Million to Discover Human Proteins
2022-05-27
Janssen’s First Cell Therapy Gets Europe’s Approval for Multiple Myeloma
2022-05-27
Cell and Gene Therapy Landscape in Japan is Moving Beyond Oncology
2022-05-27
New Study Reveals Hope for Recovery of Patients with Spinal Cord Injury
2022-05-27
Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer
2022-05-26
Stanford Touts Remote-Controllable CAR-T Cell Therapy
2022-05-26
Phenomix Launches The First Obesity Biobank Registry To Study Underling Phenotypes
2022-05-26
EVENT
2022-06-03
ASCO Annual Meeting
Online and on-side
2022-06-07
Digital RESI June
Online
2022-06-09
Medhospafrica
Africa
2022-06-13
BIO International Convention
San Diego, CA
2022-12-14
BIOHK2022
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!